Endoüroloji Bülteni

Yazarlar: Adem Emrah COĞUPLUGİL, Bahadır TOPUZ, Sercan YİLMAZ, Murat ZOR, Mesut GÜRDAL

Konular:Üroloji ve Nefroloji

Anahtar Kelimeler:Botulinum toxin,Intradetrusor injection,Onabotulinumtoxin-A,Overactive bladder,Resistant

Özet: Objectives: To present the results of onabotulinumtoxin-A (BONTA) injections in patients with overactive bladder (OAB) resistant to medical therapy. Material and Methods: Patients who underwent BONTA injection due to resistant OAB between 2013-2018 were included in this retrospective study. Patients who have used at least two different antimuscarinic drugs for 3 months and not improved or cannot tolerate side effects are identified as resistant OAB. The diagnosis of OAB was made by urodynamic study and/or by clinical findings. All patients were evaluated with urinalysis and urine culture, post-void residual urine measurement (PVR) and voiding diary, and/or symptom scores preoperatively and postoperatively at 2 weeks, 3 months and 6 months. Improvement was determined as continence or> 50% improvement in symptoms. All side effects were recorded. Results: 71 resistant OAB patients underwent intradetrusor 100 U BONTA injection. Mean patient age was 33,5 years (range:21-86). Improvement rates were 78,8% at 3 months and 67,6% at 6 months. Complications were as follows; clean intermittent catheterization (CIC) due to high PVR (12,6%), microscopic transient hematuria (7,1%), and acute cystitis (8,4%). High PVR values returned to normal within 5 weeks in all patients who underwent CIC. Systemic side effects or acute urinary retention did not occur. Conclusion: Intradetrusor injection of 100 U BONTA continues to be used as an effective and safe treatment method in patients with resistant OAB. 

---